Investigating penetrance of severe combined immunodeficiency variants in an adult population cohort: implications for genomic newborn screening

This study analyzing 490,640 UK Biobank genomes found that severe combined immunodeficiency (SCID) variants exhibit high penetrance and a low prevalence of biallelic pathogenic variants, supporting the inclusion of SCID in genomic newborn screening while highlighting the need for careful reporting of hypomorphic variants.

The Gist

Imagine your body's immune system as a highly trained security guard force protecting a castle (your body) from invaders like bacteria and viruses.

Severe Combined Immunodeficiency (SCID) is like a scenario where the castle's security force is completely missing or broken from the very beginning. Without this protection, even the tiniest, harmless germs can become deadly invaders. Usually, this is a crisis that happens in babies within their first few months of life. If not fixed immediately, it's fatal. But if caught early, doctors can rebuild the security force, and the child can live a normal, healthy life.

Because of this urgency, many places already test newborns for SCID. Now, scientists are asking: What if we used our entire genetic code (our "instruction manual") to screen for this before babies are even born? This is called genomic newborn screening.

However, there's a catch. Sometimes, the "instruction manual" has typos (genetic variants) that look like they would break the security force, but in reality, the force still works just fine. If we flag every single typo, we might panic parents and run unnecessary tests on healthy babies. This is what scientists call low penetrance—the genetic error exists, but the disease doesn't actually show up.

So, what did this study do?
The researchers acted like genetic detectives. They looked at the DNA of nearly 500,000 adults (the UK Biobank) to see how many people actually had the "broken security force" typos.

Here is what they found, using some simple analogies:

1. The "One-Handed" Clue: They found about 4,200 people who had one bad typo in their instructions. Think of this like having a spare tire in your car that's flat. It's a flaw, but since you have a second, good tire (the other copy of the gene), your car still drives perfectly fine. These people are "carriers" but are completely healthy.
2. The "Double-Flaw" Mystery: They were looking for people who had two bad typos (one from mom, one from dad), which is the recipe for SCID. Out of 500,000 people, they only found 6 people with this double flaw.
3. The Reality Check: Even among those 6, detailed investigation showed that only 2 or 3 of them actually had a broken immune system that would need fixing. The others had the "broken" genes but were still healthy. This suggests that even when you have the "broken" instructions, the body sometimes finds a way to patch it up.

What does this mean for the future?
The study concludes that if we start screening newborns using their whole genome, we won't be sending 1 in 100 babies for scary follow-up tests. Instead, it's more like 1 in 100,000.

The Takeaway:
SCID is still a perfect candidate for this new type of screening because it's so dangerous and treatable. However, the study warns doctors: Don't sound the alarm for every single genetic typo. Just like a mechanic wouldn't scrap a car because of a single scratch on the bumper, we need to be careful not to over-diagnose babies who have genetic "typos" that don't actually cause the disease.

In short: The plan to screen babies using their DNA is a great idea, but we need to be smart detectives to avoid false alarms.

Technical Summary

1. Problem Statement

Severe Combined Immunodeficiency (SCID) is a heterogeneous, recessive disorder characterized by severe, recurrent infections in early infancy, often proving fatal without prompt treatment. While SCID is a standard target for newborn screening (NBS) and emerging genomic newborn screening (gNBS) programs, a critical knowledge gap exists regarding the penetrance of SCID-associated variants in the general population.

In a "genotype-first" gNBS approach, identifying individuals with pathogenic variants without immediate phenotypic confirmation can lead to the reporting of low-penetrance variants. This creates a risk of false positives, unnecessary follow-up testing, and parental anxiety. There is an urgent need to estimate the true prevalence and penetrance of these variants in large population cohorts to refine screening protocols and mitigate the consequences of reporting variants that may not result in clinical disease.

2. Methodology

The study utilized a large-scale, population-based approach to assess SCID variant penetrance:

• Cohort: The analysis was conducted on the UK Biobank, utilizing whole-genome sequencing (WGS) data from 490,640 individuals.
• Gene Targeting: Researchers interrogated 16 genes known to be associated with SCID for potentially causal variations.
• Variant Classification: The study focused on identifying:
  • Single heterozygous pathogenic variants (carriers).
  • Biallelic pathogenic variants (homozygous, hemizygous, or double heterozygous), which are the genotypic requirement for recessive SCID.
• Phenotypic Correlation: The researchers cross-referenced genotypic findings with clinical data to identify affected versus unaffected individuals harboring biallelic variants.
• Curation: A detailed variant curation process was applied to distinguish high-confidence pathogenic variants from hypomorphic (partially functional) variants.

3. Key Contributions

• Population Penetrance Estimation: The study provides one of the largest empirical estimates of SCID variant penetrance in a general adult population, moving beyond theoretical models.
• gNBS Feasibility Analysis: It directly addresses the operational challenges of implementing SCID screening in a genomic context by quantifying the expected false-positive rate and the burden of follow-up testing.
• Variant Curation Framework: The study highlights the critical importance of distinguishing between fully pathogenic and hypomorphic variants when interpreting genomic data for screening purposes.

4. Results

• Carrier Frequency: The study identified 4,206 carriers of single heterozygous pathogenic variants, representing approximately 1% of the cohort.
• Biallelic Variant Frequency: Only 6 individuals were found to be homozygous, hemizygous, or double heterozygous for relevant pathogenic variants.
• Clinical Correlation:
  • Of the 6 individuals with biallelic variants, 3 were identified as likely requiring further clinical testing if identified via gNBS.
  • This suggests a follow-up rate of fewer than 1 in 100,000 newborns due to SCID variants.
  • After rigorous curation, only 2 unaffected individuals were confirmed to likely harbor biallelic pathogenic variants, indicating reduced penetrance for specific genotypes.
• Variant Specificity: The results indicate that while pathogenic variants exist, the subset that leads to clinical SCID in a newborn setting is extremely rare, and many identified biallelic carriers in adults may be asymptomatic due to hypomorphic variants or other modifying factors.

5. Significance and Implications

• Validation of gNBS for SCID: Despite the presence of low-penetrance variants, the study concludes that SCID remains an excellent candidate for inclusion in genomic newborn screening. This is due to the condition's high severity, the availability of effective treatments (e.g., HSCT, gene therapy), and the low false-positive rate (fewer than 1 in 100,000).
• Refining Screening Protocols: The findings support the implementation of gNBS but emphasize the necessity of careful variant curation. Screening programs must exercise caution when reporting hypomorphic variants to avoid over-diagnosis and unnecessary medical intervention.
• Public Health Impact: By establishing that the burden of follow-up testing is minimal, the study alleviates concerns regarding the scalability and cost-effectiveness of adding SCID to large-scale genomic newborn screening programs.